This review outlines the clinical management of cardiogenic shock, highlighting pharmacological therapies, mechanical circulatory support, and future directions including artificial intelligence.
This review outlines current treatments, challenges, and future directions for cardiogenic shock, including the potential of AI and wearable monitors for earlier detection.
Cardiogenic shock is a life-threatening condition caused by the heart’s sudden inability to pump sufficient blood to maintain adequate tissue perfusion, most commonly occurring following a myocardial infarction or acute decompensated heart failure. The resultant hypoperfusion can quickly progress to end-organ failure and ultimately death if not treated urgently. This review explores the management of cardiogenic shock, highlighting current treatments, their effectiveness, and the challenges faced by healthcare providers. It looks at both pharmacological therapies and devices used for cardiac support, including mechanical circulatory support and emergency revascularisation procedures to restore blood flow. We also examine how different stages of shock affect survival and how new technologies including artificial intelligence and wearable monitors could help detect and treat this condition earlier. In addition, this review discusses the significant pressure that cardiogenic shock places on healthcare provision, including the typical financial cost of treatment in the UK, resource utilisation and regional disparities. Finally, we outline future directions for trial design, better prevention, more rapid diagnosis and improved treatments that could improve morbidity and mortality.
Aubdool et al. (Tue,) conducted a review in Cardiogenic shock. This review outlines the clinical management of cardiogenic shock, highlighting pharmacological therapies, mechanical circulatory support, and future directions including artificial intelligence.